Compound | Dose | t1/2, plasma | Cmax, plasma | Cmax, brain | Tmax, plasma | Bioavailability | Brain/Plasma Ratioa |
---|---|---|---|---|---|---|---|
mg / kg | h | ng / ml | ng / g | H | % | ||
RGH-237 | 10 (p.o.) | 2.0 ± 0.7 | 2876 ± 371 | 110 | 0.8 ± 0.4 | 41 | 0.047 |
RGH-237 | 10 (s.c.) | 1.8 ± 0.5 | 4397 ± 2041 | n.d. | 1.0 ± 0 | 51 | n.d. |
BP-897 | 10 (p.o.) | n.c. | 29.4 ± 10.6 | n.d. | 0.55 ± 0.41 | n.c. | n.c. |
BP-897 | 10 (s.c.) | 1.3 | 344 ± 39.5 | 2119 | 0.25 ± 0 | 36 | 4.9 |
SB-277011-A | 10 (p.o.) | 1.9 ± 0.4 | 2166 ± 197 | n.d. | 1.0 ± 0 | 63 | n.d. |
n.c., not calculated; n.d., not determined
↵ a Area under the curvelast,brain/area under the curvelast,plasma